eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperparathyroidism |
| Comorbidity | C0022661|chronic kidney disease |
| Sentences | 51 |
| PubMedID- 23521343 | hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. |
| PubMedID- 22930877 | Secondary hyperparathyroidism in patients with chronic kidney disease (ckd) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia. |
| PubMedID- 22622503 | Moreover, during the past decade, the intense research on mineral disorders, seen in the course of chronic kidney disease with secondary hyperparathyroidism, has revealed the interplay between ca(2+) and mg(2+) homeostasis. |
| PubMedID- 20435429 | Total parathyroidectomy without autotransplantation for the treatment of secondary hyperparathyroidism associated with chronic kidney disease: clinical and laboratory long-term follow-up. |
| PubMedID- 25949433 | hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary? |
| PubMedID- 23713879 | Paricalcitol is a synthetic vitamin d2 agonist of the vdr approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd). |
| PubMedID- 24884838 | This report describes the activity of amg 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease on dialysis. |
| PubMedID- 21318141 | Until now superiority of the third generation of pth kits, measuring only the concentration of “native” 1-84-pth, has not been proven for diagnosis of primary hyperparathyroidism, at least in patients without chronic kidney disease. |
| PubMedID- 25950238 | Long-term outcomes of total parathyroidectomy with or without autoimplantation for hyperparathyroidism in chronic kidney disease: a meta-analysis. |
| PubMedID- 23760489 | Synthetic analogs of 1,25(oh) 2d that are less calcemic, such as paricalcitol (19-nor-1,25-dihydroxyvitamin d 2), are used to treat hyperparathyroidism associated with chronic kidney disease. |
| PubMedID- 24089157 | High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in argentina. |
| PubMedID- 23140920 | Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (tp) may be indicated for secondary hyperparathyroidism (2hpt) in patients with chronic kidney disease (ckd), not eligible for kidney transplantation. |
| PubMedID- 21460359 | Diuretics and secondary hyperparathyroidism in chronic kidney disease. |
| PubMedID- 25949409 | In 2004, the us food and drug administration (fda) approved cinacalcet-hcl (sensipar®, amgen) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 22293059 | Therefore, in everyday clinical practice, hypercalcemia and hyperphosphatemia often limits the ability to suppress secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 25789142 | [15] in fact, a reduction in 1,25(oh) 2d secondary to reduced 1-α hydroxylase enzyme activity contributes to the development of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 22007637 | Background: the calcimimetic cinacalcet is approved for treating secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 26411713 | The relation may guide physician to suspect hyperparathyroidism in chronic kidney disease patients and manage the complications related to hyperparathyroidism like renal mineral bone disease, anemia resistant to erythropoietin. |
| PubMedID- 20056760 | Background and objectives: the optimal treatment of secondary hyperparathyroidism in chronic kidney disease (ckd) is unknown. |
| PubMedID- 23877588 | Fgf-23 and secondary hyperparathyroidism in chronic kidney disease. |
| PubMedID- 22942242 | The calcium-sensing receptor (casr)-specific allosteric modulator cinacalcet has revolutionized the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 26429172 | Vascular calcifications represent a severe complication of secondary hyperparathyroidism in patients with chronic kidney disease (ckd) stage 5. |
| PubMedID- 22022934 | Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis. |
| PubMedID- 23018042 | In chronic kidney disease patients with secondary hyperparathyroidism (shpt), the recommended k/doqi target serum levels of parathyroid hormone (pth), calcium (ca) and phosphorus (p) are difficult to reach and maintain stable. |
| PubMedID- 24377047 | Hifu therapy has been used in japan [50], but in other countries this therapy has been reported with contradictory results, sometimes failing [51] and sometimes showing improved results in secondary hyperparathyroidism treatment in patients with chronic kidney disease [52]. |
| PubMedID- 22868729 | [management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in togo]. |
| PubMedID- 23960343 | This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stage 4 in a prospective clinical trial. |
| PubMedID- 23833757 | Purpose: the national kidney foundation kidney disease outcomes quality initiative (nkf-k/doqi) 2003 has established guidelines for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease - minerals and bone disorder (ckd-mbd). |
| PubMedID- 25446887 | Vitamin d insufficiency is prevalent in chronic kidney disease (ckd) and associated with secondary hyperparathyroidism (shpt) and increased risk of bone and vascular disease. |
| PubMedID- 23330456 | The calcimimetic agent cinacalcet is approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. |
| PubMedID- 23222688 | In the context of a pharmacokinetic (pk)/pharmacodynamic study of cinacalcet in dialysis-dependent chronic kidney disease children with secondary hyperparathyroidism, we describe the development and validation of a new, rapid, simple, and economical liquid chromatography-tandem mass spectrometry (lc-ms/ms) micromethod for quantifying cinacalcet plasma concentrations. |
| PubMedID- 22997972 | Background: secondary hyperparathyroidism develops frequently with chronic kidney disease (ckd) and is associated with poor outcome. |
| PubMedID- 21885174 | Background: the efficacy of 25-hydroxyvitamin d (25[oh]d) supplementation versus vitamin d receptor activators for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stages 3 or 4 and vitamin d deficiency is unclear. |
| PubMedID- 24202304 | Objective: calcitriol and various analogs are commonly used to suppress secondary hyperparathyroidism in chronic kidney disease but may also exacerbate vascular calcification. |
| PubMedID- 22536505 | The more effective treatment of secondary hyperparathyroidism in chronic kidney disease is probably the reason the calcium-phosphate metabolism disturbances are not the main problem in the development of sarcopenia. |
| PubMedID- 21695192 | In the clinical settings, administration of 1,25(oh)2d3 is currently used as a standard of care treatment combating both 1,25(oh)2d3 deficiency and secondary hyperparathyroidism in children with chronic kidney disease-mineral and bone disorder (ckd-mbd) [9]. |
| PubMedID- 26306956 | Paricalcitol has proved effective to control secondary hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients, with a low hypercalcaemia incidence. |
| PubMedID- 21058933 | Importance of the field: chronic kidney disease is frequently complicated by secondary hyperparathyroidism, which causes bone disease and vascular calcification, leading to increased risk of morbidity and mortality. |
| PubMedID- 24402111 | [clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease]. |
| PubMedID- 20090879 | The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 22015443 | Background: the recently developed non-invasive high-intensity focussed ultrasound (hifu) technique for the destruction of parathyroid adenomas could also be of interest for the treatment of secondary hyperparathyroidism (shp) in patients with chronic kidney disease (ckd). |
| PubMedID- 26429790 | Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the european society of endocrine surgeons. |
| PubMedID- 25905209 | hyperparathyroidism in chronic kidney disease |
| PubMedID- 25984155 | Hyperphosphataemia is an established risk factor for cardiovascular mortality, renal osteodystrophy and secondary hyperparathyroidism in patients with end-stage chronic kidney disease (ckd) under renal replacement therapy. |
| PubMedID- 21076444 | Secondary hyperparathyroidism in chronic kidney disease (ckd) develops in response to disturbances in calcium and phosphate metabolism associated with ckd, including fgf23 and klotho. |
| PubMedID- 25028644 | The development of calcimimetics, which are synthetic allosteric modulators of the calcium-sensing receptor (car), has been a breakthrough in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (ckd). |
| PubMedID- 25490118 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. |
| PubMedID- 22210744 | Indeed, the second-generation calcimimetic, cinacalcet, has proven clinically useful in the treatment of chronic kidney disease patients with secondary hyperparathyroidism but is not widely used in earlier stages of renal disease due to the potential to predispose such patients to hypocalcaemia and hyperphosphatemia. |
| PubMedID- 22503212 | Background: cinacalcet (krn1493) was developed to manage secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 25701941 | Gene mutations in chronic kidney disease patients with secondary hyperparathyroidism and sagliker syndrome. |
Page: 1 2